1. Optimal timing for initiation of highly active antiretroviral therapy in treatment-naïve human immunodeficiency virus-1-infected individuals presenting with AIDS-defining diseases: the experience of the PISCIS Cohort 
C. Manzardo, A. Esteve, N. Ortega, D. Podzamczer, J. Murillas, F. Segura, L. Force, C. Tural, J. Vilaró, A. Masabeu, I. Garcia, M. Guadarrama, E. Ferrer, M. Riera, G. Navarro, B. Clotet, J.M. Gatell, J. Casabona, J.M. Miró 
Clinical Microbiology and Infection 
Volume 19, Issue 7, Pages (July 2013)
DOI: /j x
Copyright © 2013 European Society of Clinical Infectious Diseases Terms and Conditions

2. FIG. 1
Flow chart of exclusion from the study population. Of the 117 patients excluded because follow-up was <30 days, 35 were lost to follow-up and 82 presented with AIDS and/or died (43 presented with AIDS, 36 died and three presented with AIDS and died during the 30-day period). The 108 patients excluded because they did not meet the criteria for assignment to the early or late group were distributed as follows: three patients presented with AIDS or died during the late period (30–270 days) but started highly active antiretroviral therapy (HAART) after day 270; five patients presented with AIDS or died during days 270–365; 82 patients who did not present with an event during follow-up did not start HAART or started after day 270; and 18 patients started other antiretroviral treatments not classified as HAART.
Clinical Microbiology and Infection  , DOI: ( /j x)
Copyright © 2013 European Society of Clinical Infectious Diseases Terms and Conditions

3. FIG. 2
Overall cumulative incidence of AIDS/death in antiretroviral-naïve patients presenting with an AIDS-defining disease (N = 625). p-Values after comparison between the early and deferred highly active antiretroviral therapy (HAART) groups: log-rank test.
Clinical Microbiology and Infection  , DOI: ( /j x)
Copyright © 2013 European Society of Clinical Infectious Diseases Terms and Conditions